Robust Plasma Sales, New Innovations Aid Haemonetics Stock

Haemonetics (HAE) has been banking on its growth drivers like the Plasma and Hospital business. New product launches also lead to market expansion. The stock carries a Zacks Rank #2 (Buy) currently. Major Factors Driving HAE Stock Haemonetics' Plasma business continues to grow, banking on an expanding end-user market for plasma-derived biopharmaceuticals. In the second quarter of 2024, U.S. collection volume growth was robust. Both North America software and Europe disposable revenues witnessed double-digit ...